

# Role of mid thigh cross sectional area by computed tomography (MMTCSA<sub>CT</sub>), C-reactive protein to assess effect of pulmonary rehabilitation (PR) in interstitial lung diseases (ILDs)

## Introduction

ILDs are a diverse group of lung diseases that are characterized by chronic inflammation and progressive fibrosis of the pulmonary interstitium.<sup>1</sup> Data on the prevalence of ILD is scattered, scanty and inaccurate too. The prevalence in New Mexico was 80.9 cases per 100,000 population for men and 62.2 cases per 100,000 population for women and the incidence of ILD was 31.5 per 100,000 persons per year for men and 26.1 per 100,000 persons per year for women with idiopathic pulmonary fibrosis (IPF) accounted for 46.2% of all ILDs diagnosed in men, and 44.2% in women.<sup>2</sup>

Patients with ILDs often report decreases in exercise tolerance, activities of daily living, muscle force, health-related quality of life (HRQOL), and increases in levels of fatigue and dyspnoea<sup>3</sup> and those with the greatest exercise limitation have the worst quality of life.<sup>4</sup> The mechanisms of reduced exercise capacity in ILD appear to be multifactorial. Destruction of the pulmonary capillary bed results in ventilation-perfusion mismatch, impairment of gaseous exchange and oxygen diffusion limitation.<sup>5</sup> Circulatory limitation aggravates the problem which results from pulmonary capillary destruction and pulmonary vasoconstriction ultimately leading to pulmonary hypertension and cardiac dysfunction in some patients.<sup>6</sup> Ventilatory limitation to exercise<sup>7</sup> and peripheral muscle dysfunction also play a significant role in limiting exercise capacity,<sup>8</sup> as a result of physical deconditioning. Patients who experience dyspnoea and fatigue with functional activity commonly reduce their activity levels, leading to a vicious cycle of worsening exercise capacity and increasing symptoms<sup>9</sup> Systemic inflammation may also leads to muscle wasting and peripheral muscle dysfunction like in COPD.<sup>10</sup> Cytokines play an important role in the pathogenesis of ILD and several inflammatory mediators have been shown to be increased in ILDs which include CRP, IL-8, IL-10, TNF- $\alpha$ , IFN- $\gamma$ , IL-2, MMP-9, MMP-7, etc. Moreover, treatments for ILD such as corticosteroids and immunosuppressive therapy further may lead to drug induced myopathy.<sup>9</sup>

Pulmonary rehabilitation (PR) program is a well-established and widely accepted therapeutic tool used with standard pharmacotherapy alleviates symptoms, improves the quality of life and functional capacity in patients with chronic lung diseases like COPD, bronchiectasis and, thus optimize a patient's physical and psychological functioning.<sup>11</sup> Exercise training is the cornerstone of pulmonary rehabilitation and is the best available means of improving muscle function in chronic lung disease. However, very little is known about the effect of pulmonary rehabilitation over systemic inflammation, muscle mass and exercise capacity in patients of ILD. Holland et al.<sup>12</sup> demonstrated short term improvement in exercise capacity and symptoms in ILD patients after 8 weeks of supervised exercise training. Ferreira et al.<sup>13</sup> showed

a clinically significant improvement in both functional status and dyspnea after 6 to 8 weeks of outpatient PR. This benefit was more pronounced in the patients with the worst baseline walk distances. Nishiyama et al.<sup>14</sup> showed 10-week programme of exercise training resulted in marked improvement in both exercise capacity and health related quality of life in patients of IPF. Meta-analysis of the studies on physical training for interstitial lung diseases by Holland et al.<sup>9</sup> demonstrated improvement in functional exercise capacity, dyspnoea and quality of life immediately following training. However, there was little evidence regarding long-term effects of physical training. Salhi et al.<sup>15</sup> showed that pulmonary rehabilitation in patients with restrictive lung diseases leads to clinically relevant improvements of the maximal and submaximal exercise capacity, muscle force, and quality of life after 12 weeks and with further improvements after 24 weeks with just 16% drop-out i.e half the dropout rate in COPD, whose drop-out rate may reach up to 31%.

Mid thigh muscle cross-sectional area (MTCSA) is an index of muscle mass which has frequently been studied in stable COPD patients. Prediction of MTCSA from anthropometric parameters is not sufficiently accurate for clinical purposes in patients with COPD. Marquis et al.<sup>16</sup> used MMTCSA<sub>CT</sub> in their study and found that it is a better predictor of mortality than body mass index and MMTCSA<sub>CT</sub> has a strong impact on mortality in COPD patients with an FEV<sub>1</sub><50% predicted. Fiatarone et al.<sup>17</sup> found a significant increase in mid-thigh muscle area with marked increases in both quadriceps (9%) and hamstring and adductor areas (8.4%) in response to 8wk of resistance training, without changes in subcutaneous or intramuscular adipose tissue. Recently Ferrari et al.<sup>18</sup> showed inverse relationship between inflammatory markers and muscle mass using MMTCSA<sub>CT</sub>

Volume 3 Issue 6 - 2016

**Brijesh Prajapat**  
PGIMS Rohtak, India

**Correspondence:** Brijesh Prajapat, PGIMS Rohtak, A-38 ganesh nagar pandav nagar complex Delhi-92, India, Tel 08607731947, Email dr.brijeshprajapat@gmail.com

**Received:** July 04, 2016 | **Published:** December 15, 2016

We hypothesize that PR in ILD patients leads to increase in muscle mass as calculated by MTCSA<sub>CT</sub> scan, decrease in systemic inflammation and improvement in exercise capacity (6MWD) and quality of life (St. George respiratory questionnaire).

## Materials and methods

The study was a prospective nonrandomized study conducted at Vishwanathan Chest Hospital, Vallabhbai Patel Chest Institute (VPCI), University of Delhi. Both male and female patients diagnosed as ILD were included in the study from the outpatient department. The diagnosis of ILD was based on clinical history consistent with ILD, chest xray, pulmonary function test, high resolution CT scan (HRCT), bronchoalveolar lavage (BAL) and transbronchial lung biopsy (TBLB).

Inclusion criteria were age more than 18yrs and history, examination, PFT consistent with ILD. Exclusion criteria were pregnancy, physiological impairment impeding training program, presence of systemic disease, acute respiratory infection in the last 4weeks. The baseline values of the following parameters were measured at the time of inclusion in to the study: Complete pulmonary function test (PFT), Mid thigh cross sectional area CT (MTCSA<sub>CT</sub>) (mm<sup>2</sup>), Six minute walk distance (6MWD) and SGRQ. The patients then received standard therapy as per BTS guidelines<sup>19</sup> in addition to pulmonary rehabilitation for eight weeks and the variables were again measured at the end of eight weeks of PR.

### Exit from the Study

- I. Patients request
- II. Non compliance with study protocol
- III. Skipped more than 1 week of training program.
- IV. Any acute exacerbation requiring hospitalization and use of antibiotics and/or increase in dose of oral steroids.

### Pulmonary function tests

Spirometry was performed on a computerized apparatus-Benchmark (P. K. Morgan and Co. Ltd. Chatham, Kent England). FVC, FEV<sub>1</sub>, FEV<sub>1</sub>/FVC%, RV, TLC, DLCO were obtained as per the recommendations of the American Thoracic Society.<sup>20</sup>

### Midthigh muscle cross-sectional area (MTCSA<sub>CT</sub>)

A computed tomography of the right and left thigh, halfway between the pubic symphysis and the inferior condyle of the femur was performed using a third generation scanner. Each image was 10-mm thick and was taken at 120KV and 200mA with a scanning time of 1 second while the subject was lying in the supine position. The thigh muscle cross-sectional area (CSA) was obtained by measuring the surface area of the tissue with a density of 40 to 100 hounsfield units (HU). The MTCSA<sub>CT</sub> was calculated by taking average for right and left thighs.

### Six minute walk test (6mwt)

6MWT was performed on a flat, straight, enclosed corridor with a hard surface as per the ATS guidelines.<sup>21</sup> Supplemental oxygen was used during the test in patients who were already on LTOT or in those who desaturated below 88%.

### Pulmonary rehabilitation program

The pulmonary rehabilitation program comprised minimum of

90minutes of supervised exercise training for lower and upper limbs, performed over separate sessions each day, three days a week, for 8 weeks. Lower limbs training included leg-ergometry and treadmill walking. Training of the upper limbs included arm-ergometry and free weights. Simultaneous upper and lower limb training was performed on Semi-Recumbent Whole Body Exerciser. Exercise intensity during each session was incremental and graded according to symptom tolerance and was of 20minutes duration. Patients also attended educational sessions on topics such as breathing exercises, energy conservation, lung health, medications and stress management.<sup>11</sup>

## Statistical analysis

Statistical analysis was done using Graph pad 5.03 version. The data were presented as mean±standard error (SE). The difference in the mean baseline values of various measurements within the group and between the groups was made using student's t-test. A p value of <0.05 was considered significant.

## Results

21 patients were enrolled. Eighteen patients completed the study and three patients dropped out as they refused for PR programme after 1week. 11 were females and the mean age was 52.17±2.416years. The demographic and clinical characteristics of the study group is given in the Table 1.


**Table 1** Demographic characteristics of study group

Parameters	Study group
	Mean±S.E
Age (Years)	52.17±2.416
BMI (kg/m <sup>2</sup> )	26.31±1.066
Male: Female	7:11
Occupation	Housewife (11) 61.11%
	Shop keeper(2) 11.1%
	Clerk (1) 5.55%
	Farmer (1) 5.55%
	Retired bank officer (2) 11.11%
Smoking Status	Tutor (1) 5.55%
	Smoker (6) 33.33%
	Nonsmoker (12) 66.66%
Pack Years	5.000±2.425
Disease Duration (yrs)	4.250±0.4753
Hb (g/dl)	12.94±0.3511
Total Proteins (gm/dl)	5.466±0.2255
Albumin (gm/dl)	3.068±0.1846


Decrease in CRP mean value at the end of 8 weeks was found as compared to baseline level although the difference didn't reach the mark of statistically significant (p=0.08) (Table 2), (Figure 1). MTCSA<sub>CT</sub> showed statistically significant increase at the end of 8 weeks compared to baseline level (p=0.0089) (Table 2), (Figure 2). At the end of 8 weeks, six minute walk test showed statistically significant improvement from baseline in the study group (p<0.0001) (Figure 3). SGRQ score was also improved post PR (p<0.0001) (Figure 4). Arterial blood gas parameters, blood lactate levels and pulmonary function tests did not show significant change at the end of 8 week. Comparison of various parameters done pre and post PR programme are summarized in Table 2.

**Table 2** Comparison of various parameters in study group (N=18)


Parameters	At base line	AT 8 weeks	P value
	Mean±S.E.	Mean±S.E.	
CRP (mg/L)	5.794±0.8470	5.286±0.7400	p=0.0838
MTCSA <sub>CT</sub> (mm <sup>2</sup> )	9336±464.6	9696±463.5	p=0.0089
6MWT (m)	411.6±15.27	457.9±14.06	p<0.0001
Lactate (mmol/L)	1.156±0.1181	1.011±0.1174	p= 0.2067
SGRQ	58.51± 1.505	52.68±1.659	P<0.0001
Pao <sub>2</sub> (mmHg)	63.72±2.148	64.17±1.905	p=0.4395
Paco <sub>2</sub> (mmHg)	39.32±1.183	39.27±0.8807	p=0.9631
Sao <sub>2</sub> (%)	91.84±1.241	92.56±1.155	p=0.1277
FEV <sub>1</sub> (L)	1.553±0.1189	1.577±0.1204	p=0.3905
FVC (L)	1.859±0.1414	1.894±0.1422	p=0.3905
RV(L)	1.066±0.09290	1.154±0.1056	p=0.1726
TLC(L)	2.889±0.1581	3.125±0.1951	p=0.0600
DLCO(ml/min/mmHg)	9.246±1.025	9.819±1.004	p=0.1726




**Figure 1** Difference in C-reactive protein (CRP) level in the study group before and after PR program.



**Figure 2** Difference in Mid thigh cross sectional area using CT scan (MTCSA<sub>CT</sub>) in the study group before and after PR program (p=0.0089).



**Figure 3** Difference in six minute walk distance (6MWD) in the study group before and after PR program (p<0.0001).



**Figure 4** Difference in SGRQ score in the study group before and after PR program (p<0.0001).

## Discussion

We studied the effects of pulmonary rehabilitation on systemic inflammation (CRP levels), MTCSA using CT scan, exercise capacity and quality of life.

CRP reflects total systemic burden of inflammation of individuals and is used as a predictor of hospitalization and mortality in patients with chronic respiratory failure. It is higher in patients in patients with poor FEV<sub>1</sub> value and in those who smoke. CRP level predicts cardiovascular mortality. Drent and coworkers demonstrated that a moderate increase in serum CRP is implicated in Sarcoidosis<sup>22</sup> while Richards et al.<sup>22</sup> found higher serum levels of CRP in myositis associated ILDs.<sup>23</sup> In the present study, CRP levels were higher in the study group supporting the results of previous studies. Mattusch and colleagues investigated the influence of exercise training on CRP level in healthy subjects and found that the baseline CRP level in 10 out of 12 runners was significantly reduced after training.<sup>24</sup> This study therefore supports the view that intensive regular exercise has a systemic anti-inflammatory effect in healthy subjects and the research has potential implications for patients with ILDs. HERITAGE Family Study of exercise in healthy sedentary individuals also suggested that beneficial reductions in CRP levels after training are greatest in those with baseline levels higher than 3mg/L.<sup>25</sup> In our study group mean CRP level in at baseline was high (5.794±0.8470mg/l). In addition, we found CRP levels were decreased, although not significantly after 8 weeks of PR program. Apart from exercise, the medications that can decrease CRP level include inhaled and systemic corticosteroids. The patients in our study receiving pharmacotherapy in the form of corticosteroids and other immunosuppressive drugs were given the same dose of drugs throughout the study period. The decrease in mean value in might be due to the absence of infection and exacerbation during the entire study period which are known to increase the CRP levels. Although the decrease in mean CRP level was not statistically significant still it indicates that pulmonary rehabilitation may have additive effect on the decrease in CRP level. This will provide a promising aspect for further research and highlights the importance of pulmonary rehabilitation in the management of ILD.

Body weight loss is seen in patients with ILD. Although body weight is a useful prognosis marker in ILD, it is not sensitive to changes in body composition as it can be increased or normal despite the presence of muscle wasting. Marquis et al used MTCSA<sub>CT</sub> in their study and found that MTCSA<sub>CT</sub> is a better predictor of mortality than body mass index and MTCSA<sub>CT</sub> has a strong impact on mortality in COPD patients with an FEV<sub>1</sub><50% predicted.<sup>16</sup> Fiatarone et al.<sup>17</sup> found a significant increase in mid-thigh muscle area with marked increases in both quadriceps (9%) and hamstring and adductor areas (8.4%) in response to 8wk of resistance training, without changes in subcutaneous or intramuscular adipose tissue. In our study, the mean value of MTCSA at the end of 8 weeks was increased to 9696±463.5mm<sup>2</sup>. The increase in mean value from baseline was clinically significant (p=0.0089). Ferrari et al showed an inverse relationship between systemic inflammation and MTCSA<sub>CT</sub> in stable COPD patient.<sup>18</sup> In this study, we too found that MTCSA<sub>CT</sub> increased while CRP decreased after PR program.

To the best of our knowledge, no follow up study has been done to see the change in MTCSA<sub>CT</sub> after pulmonary rehabilitation in ILD patients. Muscle wasting should be considered as a serious complication in ILD and other chronic illnesses with important implications for survival. Gain in muscle mass and strength seems to be associated with better exercise tolerance and survival of ILD patients. Thus, improving peripheral muscle function could be a reasonable therapeutic target in these groups.

6MWT is used to assess the functional capacity in ILD and other chronic respiratory diseases patients. This minimum clinically

important distance (MCID) of 54m is based on the cross-sectional study of Redelmeir on 112 COPD patients attending a residential pulmonary rehabilitation program.<sup>26</sup> Lederer et al.<sup>27</sup> showed that the lower 6MWD is strongly and independently associated with an increased mortality rate for wait-listed patients classified as having IPF for lung transplantation and 6MWD was a better predictor of death at 6 month than was FVC % predicted.

Holland<sup>28</sup> showed that small differences in six-minute walk distance (6MWD), in the range 29–34m, may be clinically significant for people with diffuse parenchymal lung disease. In our study, the mean value of 6MWD was 411.6±15.27m. The mean value of 6MWD at the end of PR program was increased to 457.9±14.6m compared to baseline (p<0.0001). The impairment of exercise capacity is a central issue in patients with ILD patients. In clinical practice, the 6-minute walk test (6MWT) and the incremental shuttle walking test are commonly used to assess changes in functional exercise capacity following pulmonary rehabilitation with the primary outcome reported being the distance walked during the test. The 6MWT is also be used as a one-time measure of functional status of patients, as well as a predictor of morbidity and mortality in ILD patients.<sup>27</sup>

In the present study there was a statistically significant reduction in SGRQ score after PR program of 8 weeks.

The mean total score before PR program was (58.51±1.505) and after PR program was (52.68±1.659) with (P<0.0001). The results supported the findings of previous studies. Nishiyama et al.<sup>14</sup> also found a statistically significant improvement in the total score of SGRQ score in rehabilitated IPF group than the control group with (P<0.01). Jastrzebski et al.<sup>29</sup> found a statistically significant improvement in daily physical activities and in HRQL measured by SF-36 and SGRQ after 12weeks of PR program. Patients with advanced lung fibrosis may be too dyspneic to leave the house or to walk suggesting a clear lack of regular daily physical activities in these patients. Reduced daily physical activity may lead to loss of physical fitness and reduced quality of life seen in patients with chronic lung disease.<sup>29,30</sup>

Our study has some limitations. First, the study sample was small and thus a large sample size is required to establish the firm role of PR in ILD patients. Second, it was nonrandomized trial and thus a randomized trial is needed in this direction. Thus, we conclude that pulmonary rehabilitation program with exercise training, upper-limb, trunk, lower limb, respiratory muscle training is highly effective in improving the exercise capacity of patients of ILD compared to patients who receive standard medications only.

## Acknowledgements

None.

## Conflict of interest

The author declares no conflict of interest.

## References

1. Green FH. Overview of pulmonary fibrosis. *Chest*. 2002;122:S334–S339.
2. Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases. *Am J Respir Crit Care Med*. 1994;150(4):967–972.
3. Naji NA, Connor MC, Donnelly SC, et al. Effectiveness of pulmonary rehabilitation in restrictive lung disease. *J Cardiopulm Rehabil*. 2006;26(4):237–243.

4. Chang JA, Curtis JR, Patrick DL, et al. Assessment of health related quality of life in patients with interstitial lung disease. *Chest*. 1999;116(5):1175–1182.
5. Agusti AG, Roca J, Gea J, et al. Mechanisms of gas–exchange impairment in idiopathic pulmonary fibrosis. *American Review of Respiratory Disease*. 1991;143(2):219–225.
6. Hansen JE, Wasserman K. Pathophysiology of activity limitation in patients with interstitial lung disease. *Chest*. 1996;109(6):1566–1576.
7. Harris–Eze AO, Sridhar G, Clemens RE, et al. Role of hypoxemia and pulmonary mechanics in exercise limitation in interstitial lung disease. *American Journal of Respiratory & Critical Care Medicine*. 1996;154(4 Pt 1):994–1001.
8. Markovitz GH, Cooper CB. Exercise and interstitial lung disease. *Curr Opin Pulm Med*. 1998;4(5):272–280.
9. Holland AE, Hill C. Physical training for interstitial lung disease. *Cochrane Database Syst Rev*. 2008;4:CD006322.
10. Gea J, Pascual S, Casadevall C, et al. Muscle dysfunction in chronic obstructive pulmonary disease: update on causes and biological findings. *J Thorac Dis*. 2015;7(10):E418–E438.
11. American Thoracic Society. Pulmonary rehabilitation–99. The official statement of the American Thoracic Society. *Am J Respir Crit Care Med*. 1999;159:1666–1682.
12. Holland AE, Hill CJ, Conron M, et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. *Thorax*. 2008;63(6):549–555.
13. Ferreira A, Garvey C, Connors GL, et al. Pulmonary rehabilitation in interstitial lung diseases: Benefits and predictors of response. *Chest*. 2009;135(2):442–447.
14. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. *Respirology*. 2008;13(3):394–399.
15. Salhi B, Troosters T, Behaegel M, et al. Effects of pulmonary rehabilitation in patients of restrictive lung diseases. *Chest*. 2010;137(2):273–279.
16. Karine Marquis, Richard Debigare, Yves Lacasse, et al. Midthigh muscle cross sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2002;166(6):809–813.
17. Fiatarone MA, Marks EC, Ryan ND, et al. High–intensity strength training in nonagenarians: effects on skeletal muscle. *JAMA*. 1990;263(22):3029–3034.
18. Faganello MM, Bradley B, Branley HM, et al. Interstitial lung disease guideline: The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. *Thorax*. 2008;63(Suppl 5):v1–v58.
19. Pellegrino R, Viegi G, Brusasco V, et al. ATS/ERS Task Force: Standardisation of Lung Function Testing. *Eur Respir J*. 2005;26:948–968.
20. ATS Statement: Guidelines for the Six–Minute Walk Test. *Am J Respir Crit Care Med*. 2000;166(1):111–117.
21. Drent M, Wirnsberger RM, de Vries J, et al. Association of fatigue with an acute phase response in sarcoidosis. *Eur Respir J*. 1999;13(4):718–722.
22. Richards TJ, Eggebeen A, Gibson K, et al. Characterization and Peripheral Blood Biomarker Assessment of Jo–1 Antibody–Positive Interstitial Lung Disease. *Arthritis Rheum*. 2009;60(7):2183–2192.
23. Mattusch F, Dufaux B, Heine O, et al. Reduction of the plasma concentration of C–reactive protein following nine months of endurance training. *Int J Sports Med*. 2000;21(1):21–24.
24. Lakka TA, Lakka HM, Rankinen T, et al. Effect of exercise training on plasma levels of Creactive protein in healthy adults: the HERITAGE Family Study. *Eur Heart J*. 2005;26(19):2018–2025.
25. Redelmeyer DA, Bayoumi A, Goldstein RS, et al. Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. *Am J Respir Crit Care Med*. 1997;155(4):1278–1282.
26. Lederer DJ, Arcasoy SM, Wilt JS, et al. Six–Minute–Walk Distance Predicts Waiting List Survival in Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*. 2006;174(6):659–664.
27. Holland AE, Hill CJ, Conron M, et al. Small changes in six–minute walk distance are important in diffuse parenchymal lung disease. *Respir Med*. 2009;103(10):1430–1435.
28. Jastrzebski D, Gumola A, Gawlik R, et al. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. *J Physiol Pharmacol*. 2006;57(Suppl 4):139–148.
29. Rifaat N, Anwar E, Ali YM, et al. Value of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. *Egyptian Journal of Chest Diseases and Tuberculosis*. 2014;63(4):1013–1017.